CMPS news & sentiment — COMPASS Pathways plc

APR 8·Stock TitanMed

Compass Pathways investors can hear management live online April 14

Compass Pathways plc announced that its management will attend the Needham Virtual Healthcare Conference on April 14, 2026. They will participate in a fireside chat at 12:45 pm ET, with a live audio webcast available on the Investors section of the company's website. Compass Pathways is a biotechnology company focused on mental health, developing investigational COMP360 synthetic psilocybin treatment for conditions like treatment-resistant depression.

FEB 26·Nasdaq

COMPASS Pathways plc - Depositary Receipt (CMPS) Price Target Increased by 12.63% to 19.84

The average one-year price target for COMPASS Pathways plc (CMPS) has been increased by 12.63% to $19.84 per share, up from $17.62. This new target represents a 148.36% increase from the last closing price of $7.99. Institutional ownership in CMPS has seen a slight increase, with a bullish put/call ratio of 0.67.

FEB 24·The AI Journal

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company specializing in mental health innovation, announced its management will attend the TD Cowen 46th Annual Healthcare Conference. The conference will take place in Boston, MA, from March 2-4, 2026, where Compass Pathways will participate in a fireside chat on March 3, 2026, at 10:30am ET. A live audio webcast and replay will be available through the company's investors section.

$CMPS

Compass Pathways investors can hear management live online April 14

COMPASS Pathways plc - Depositary Receipt (CMPS) Price Target Increased by 12.63% to 19.84

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

News on $CMPS